A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

NCT06611163 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Genital Psoriasis

Interventions

DRUG: Tildrakizumab 100 mg
DRUG: Placebo

Sponsor

Sun Pharmaceutical Industries Limited